Insider buying last 90 days
No open-market insider purchases were filed for AXGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AXGN insider filing, plotted on the chart in Gekko.Open AXGN in Gekko
NASDAQ: AXGN
Axogen (AXGN) Stock Analysis & Forecast
Oct 12 close
$37.11+0.98 (+2.7%)
Gekko Brief
AI summaryOct 12 closeThis week's attention centers on fresh analyst coverage of Axogen. B of A Securities initiated coverage with a Buy rating, and Barclays initiated with an Overweight rating and a $55 price target, both citing the company's position in peripheral nerve repair and growth outlook. Separate commentary also pointed to the stock appearing undervalued on a discounted cash flow basis, alongside notes on recent price volatility and longer-term momentum despite weaker short-term returns.
AXGN closed at $37.11, up 2.7%, with the price sitting between its 50-day average of $45.21 and 200-day average of $39.09, reflecting a mixed trend. The GekkoIndex reads 71.2, placing the stock in the Buying zone. Shares trade 23.9% below the Gekko Fair Value of $48.77, a gap that stands out against the stock's 52-week range of $15.27 to $52.91.
Looking ahead, Axogen reports earnings on 4 November 2026, before the open, which falls within the next 22 days and inside a typical 20-trading-day holding window; the prior quarter's report produced a 0.5% reaction with an average absolute move of 13.7% across recent quarters. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over this calendar stretch has averaged a 15.2% move across 5 years, rising in 4 of them, a pattern worth noting alongside the eleven analyst firms currently rating the stock a buy with a consensus target of $53.82.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Axogen price vs fair value
Close $37.11200-day averageGekko Fair Value $48.77
Axogen quick facts
- Market cap
- $2.00B
- P/E ratio
- —
- Forward P/E
- 102
- EPS, TTM
- −$0.66
- Revenue, TTM
- $251.2M
- Profit margin
- -13.4%
- Dividend yield
- —
- Beta
- 1.17
- Volume
- 1.59M avg 1.40M
- 1-year return
- +126.0%
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±11.6%
- 50-day average
- $45.21
- 200-day average
- $39.09
- Next earnings
- Nov 4 before open
- Shares outstanding
- 58.67M
Axogen swing-trade checklist
Axogen scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $37.11 sits between the 50-day ($45.21) and 200-day ($39.09) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.2, Buying
Reading 71.2 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
23.9% below
Price is 23.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+15.2% on average
From this point in the calendar, the next 20 trading days averaged +15.2% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Axogen stock chart and price history
Axogen closed at $37.11 on Oct 12, 2026, +126.0% over the past year, inside a 52-week range of $15.27 to $52.91.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.0%
- 3 months
- −4.3%
- 6 months
- +10.9%
- 1 year
- +126.0%
The full AXGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AXGN in Gekko
Follow Axogen through every session
Put AXGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AXGN in GekkoFree for 7 days. No credit card required.
About Axogen
Axogen develops and markets medical devices used in surgery to repair peripheral nerves that have been cut or damaged. Its lineup includes the Avance Nerve Graft, a human nerve allograft that bridges gaps in severed nerves without requiring tissue to be taken from elsewhere in the patient's body, along with connector, protector, and cap devices made from porcine submucosa that help reconnect, shield, or cap nerve ends during reconstruction. The company also offers a membrane derived from human umbilical cord tissue to separate tissues during surgery, and a handheld tool for assessing nerve function at the skin's surface.
These products reach hospitals, surgery centers, and military medical facilities, where they are used by plastic reconstructive surgeons, hand surgeons working in orthopedics and plastic surgery, and oral and maxillofacial surgeons. Axogen sells into the United States, Canada, Germany, the United Kingdom, other parts of Europe, South Korea, and additional markets abroad.
The company is headquartered in Alachua, Florida, and its shares trade on the NASDAQ under the ticker AXGN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- axogeninc.com
Axogen GekkoIndex: the smart money zone
Axogen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.2, in the Buying zone, down 4.8 points over five sessions.
71.2Buying
Down 4.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 24 | +0.9% | −0.7% | ||
| Accumulation | 170 | +0.6% | +4.2% | ||
| Neutral | 408 | +1.7% | +6.8% | ||
| Distribution | 77 | +1.6% | +7.4% | ||
| Selling | 3 | Too few readings yet | |||
Average AXGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the AXGN price, zone by zone.Track AXGN in Gekko
Is Axogen stock overvalued? Gekko Fair Value
Axogen trades 23.9% below Gekko Fair Value of $48.77, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Axogen shares are worth, recalculated every trading day.
$48.77
Gekko Fair Value, Oct 9, 2026
23.9% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AXGN in Gekko
Axogen insider and Congress trading
No open-market insider purchases were filed for Axogen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AXGN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AXGN, plotted on the chart in Gekko.Open AXGN in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds AXGN.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Axogen earnings: next date and track record
Axogen reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- $0.13
- Revenue estimate
- $73.16M
6 of 8reports beat the EPS estimate
±13.7%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- AXGN reported Q2 2026 revenue of $69.7M, up 23.1% year-over-year, driven by broad-based growth across all markets. Breast segment led with 47% first-half growth, contributing ~2/3 of quarterly growth. Adjusted net income was $7.3M and adjusted EBITDA was $8.4M. Cash position stood at $113.4M. Gross margin declined to 72.7% from 74.2% due to unfavorable product mix from accelerating Breast business using higher-cost longer Avance grafts.
- Guidance
- Management raised full-year revenue guidance reflecting strong commercial momentum. Gross margin outlook was revised downward due to product mix shifts; pricing actions and production efficiency initiatives are planned but will not impact 2026 results. Management remains confident in strategic priorities.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | −$0.03 est −$0.04 | $69.73M est $67.10M | +0.5% |
| Apr 28, 2026 | $0.07 est $0.07 | $61.46M est $57.85M | +6.0% |
| Feb 24, 2026 | $0.07 est $0.06 | $59.90M est $59.03M | −11.8% |
| Oct 29, 2025 | $0.12 est $0.09 | $60.08M est $59.90M | +25.4% |
| Aug 5, 2025 | $0.12 est $0.06 | $56.66M est $56.89M | +9.6% |
| May 8, 2025 | −$0.02 est $0.02 | $48.56M est $53.34M | −30.6% |
| Feb 25, 2025 | $0.07 est $0.03 | $49.41M est $48.28M | +8.1% |
| Nov 7, 2024 | $0.07 est $0.01 | $48.64M est $47.44M | −17.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Axogen stock forecast and analyst price targets
Analysts’ average 12-month price target for Axogen is $53.82, +45.0% from the last close, from 11 firms rating the stock in the last 90 days.
$53.82consensus 12-month target, +45.0% from the last close
Now $37.11Avg $53.82
Low $48High $55
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Bank of America Securities | $52 | +40.1% |
| Oct 12 | Leerink Partners | $52 | +40.1% |
| Oct 6 | Barclays | $55 | +48.2% |
| Oct 5 | Lake Street | $55 | +48.2% |
| Oct 5 | Canaccord Genuity | $55 | +48.2% |
−0.7%average 20-day move after past Buying readings
+15.2%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Axogen seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Axogen averaged +15.2% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.8% | 3 of 5 |
| Next 10 trading days | −0.6% | 2 of 5 |
| Next 15 trading days | +7.8% | 4 of 5 |
| Next 20 trading days | +15.2% | 4 of 5 |
| Next 30 trading days | +12.7% | 2 of 5 |
For scale, AXGN’s typical 20-trading-day move in either direction is about 11.6%.
Axogen market cap and key statistics
Axogen’s market cap is $2.00B and revenue of $251.2M over the last twelve months.
Valuation
- Market cap
- $2.00B
- Forward P/E
- 102
- EPS, TTM
- −$0.66
- Gekko Fair Value
- $48.77
Trading
- Volume
- 1.59M
- Avg volume, 20 days
- 1.40M
- 52-week high
- $52.91
- 52-week low
- $15.27
- Shares outstanding
- 58.67M
Financials
- Revenue, TTM
- $251.2M
- Profit margin
- -13.4%
- Return on equity
- -18.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.17
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±11.6%
Axogen stock news this week
Coverage of Axogen this week reads positive: 8 positive, 0 neutral and 1 negative headlines.
- Axogen Initiated at Buy by B of A SecuritiesMoomoo, Oct 12
- AxoGen stock initiated at Buy by BofA on growth outlookInvesting.com, Oct 12
- How (AXGN) Movements Inform Risk Allocation ModelsStock Traders Daily, Oct 10
- Axogen (AXGN) Stock Could Be 26% Undervalued On Cash Flow GroundsYahoo Finance, Oct 9
- Axogen (AXGN) Is Back In The Spotlight, What Has Investors Looking Closer?Simply Wall Street, Oct 9
- Barclays Initiates Axogen at Overweight With $55 Price TargetMoomoo, Oct 8
Axogen peers
Axogen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Axogen stock FAQ
What is Axogen’s market cap?
Axogen’s market cap is $2.00B at the Oct 12, 2026 close of $37.11, with 58.67M shares outstanding.
What is the Axogen stock forecast?
The consensus analyst 12-month price target for Axogen is $53.82, +45.0% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Axogen stock overvalued or undervalued?
On Gekko’s estimate Axogen is undervalued: the Oct 12, 2026 close of $37.11 is 23.9% below Gekko Fair Value of $48.77. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Axogen report earnings next?
Axogen is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of $0.13 per share on revenue of $73.16M. Axogen beat the earnings estimate in 6 of its last 8 reports, moving 13.7% on average across the report.
What is Axogen’s 52-week high and low?
Axogen’s 52-week high is $52.91 and its 52-week low is $15.27; it closed at $37.11 on Oct 12, 2026, +126.0% over the past year.
Is Axogen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Axogen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.